Enanta Pharmaceuticals vs Wave Life Sciences
ENTA and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENTA and WVE compare
Wave Life Sciences is the larger company, worth 1.9 times as much as Enanta Pharmaceuticals ($617M against $320M).
Enanta Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −96.9% compared with −297% at Wave Life Sciences.
Wave Life Sciences scores higher on the StockData Score (10 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENTA | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $320M | $617M |
| Share price | $10.99 | $3.13 |
| Change, 1 year | −7.9% | −55.0% |
| Change, 5 years | −85.4% | −27.4% |
| Beta (5Y) | 1.14 | 1.30 |
| Employees | 120 | 317 |
| StockData Score | ||
| Total score | 2 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.9× (better) | 8.7× |
| P/B | 3.2× | 1.5× (better) |
| FCF yield | −11.5% (better) | −33.8% |
| Fair value | $9.32 | $5.15 |
| Margin of safety | −17.9% | 39.2% (better) |
| Growth | ||
| Revenue growth, 5Y average | −11.8% | 16.3% (better) |
| Profitability | ||
| Operating margin | −90.0% (better) | −321% |
| Net margin | −96.9% (better) | −297% |
| FCF margin | −56.6% (better) | −294% |
| Return on equity | −70.1% (better) | −80.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.5× | – |
| Current ratio | 3.76 | 8.38 (better) |
| Altman Z-score | −0.97 (better) | −0.98 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.6% | 92.6% |
| Held by insiders | 7.9% | 23.1% |
| Insider net buying, 12 months | −$183K | $66.5M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.9% | 13.6% |
Go deeper
- ENTA stock overview
- ENTA income statement
- ENTA valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.